Valuation: Aquestive Therapeutics, Inc.

Market Cap 495M 434M 401M 369M 696M 47.73B 707M 4.8B 1.88B 23.35B 1.86B 1.82B 80.46B P/E 2026 *
-9.74x
P/E 2027 * -10.2x
Enterprise Value 410M 359M 332M 305M 576M 39.53B 586M 3.97B 1.56B 19.34B 1.54B 1.51B 66.64B EV / Sales 2026 *
8.12x
EV / Sales 2027 * 6.88x
Free-Float
96.9%
Yield 2026 *
-
Yield 2027 * -
1 day-4.25%
1 week-2.83%
Current month-5.17%
1 month-16.24%
3 months-6.96%
6 months+13.36%
Current year-38.93%
1 week 3.81
Extreme 3.814
4.18
1 month 3.81
Extreme 3.814
5.18
Current year 2.93
Extreme 2.93
6.59
1 year 2.93
Extreme 2.93
7.55
3 years 1.25
Extreme 1.2514
7.55
5 years 0.62
Extreme 0.618
7.55
10 years 0.62
Extreme 0.618
20.7
Manager TitleAgeSince
Chief Executive Officer 50 16/05/2022
Director of Finance/CFO 67 30/12/2020
Compliance Officer - 01/04/2026
Director TitleAgeSince
Chairman 72 31/03/2024
Director/Board Member 60 31/12/2003
Director/Board Member 50 16/05/2022
Date Insider Type Main position Quantity % Market Cap.
16/07/26 Sell

Chief Executive Officer

-20,369 0.0162%
23/06/26 Fiscal year

Director

75,000 0.0598%
15/06/26 Sell

Chief Executive Officer

-25,000 0.0199%
Change 5-day change 1-year change 3-year change Capi.($)
-4.25%-2.83%-6.07%+146.56% 495M
-2.73%-2.96%+48.62%+147.27% 1,023B
-1.67%-3.47%+52.00%+47.77% 599B
-0.44%+2.17%+33.88%+78.20% 448B
-0.75%+0.30%+28.32%+21.15% 326B
-1.52%-1.19%+33.38%+35.35% 278B
-1.70%-1.82%+20.26%+15.74% 258B
-0.58%+1.11%-20.89%-40.59% 222B
-0.58%+1.03%+23.55%+56.14% 197B
-0.80%+1.38%+23.09%+66.64% 165B
Average -1.11%-0.63%+23.61%+57.42% 351.56B
Weighted average by Cap. -0.88%-1.18%+35.16%+70.59%

Financials

2026 *2027 *
Net sales 50.51M 44.27M 40.92M 37.64M 71.02M 4.87B 72.16M 489M 192M 2.38B 190M 186M 8.21B 71.92M 63.03M 58.27M 53.59M 101M 6.93B 103M 697M 273M 3.39B 270M 264M 11.69B
Net income -50.65M -44.39M -41.03M -37.74M -71.21M -4.88B -72.35M -491M -192M -2.39B -190M -186M -8.23B -47.99M -42.07M -38.88M -35.76M -67.48M -4.63B -68.56M -465M -182M -2.26B -180M -176M -7.8B
Net Debt -85M -74.5M -68.87M -63.34M -120M -8.2B -121M -823M -323M -4.01B -319M -312M -13.82B -
Logo Aquestive Therapeutics, Inc.
Aquestive Therapeutics, Inc. is a pharmaceutical company. The Company is engaged in developing orally administered and topical gel products to deliver complex molecules, providing novel alternatives to invasive and inconvenient standard of care therapies. It has four commercialized products marketed by the Company’s licensees in the United States and around the world and is the manufacturer of these licensed products. The Company also collaborates with pharmaceutical companies to bring new molecules to market using proprietary technologies, including PharmFilm, and has proven drug development and commercialization capabilities. The Company is advancing a late-stage proprietary product candidate for the treatment of severe allergic reactions, including anaphylaxis, and an early-stage epinephrine prodrug topical gel product candidate for various possible dermatology conditions. Its portfolio includes Anaphylm, AQST-108, Libervant, Suboxone, and Emylif.
Employees
147
Date Price Change Volume
20/07/26 US$3.945 -4.25% 1,434,370
17/07/26 US$4.120 +4.57% 2,356,421
16/07/26 US$3.940 -0.25% 1,921,636
15/07/26 US$3.950 -2.23% 1,887,165
14/07/26 US$4.040 -0.49% 901,361
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
3.945USD
Average target price
8.889USD
Spread / Average Target
+125.32%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AQST Stock